Chemical Structure (Levetiracetam 01)
Levetiracetam
Product Images NDC 15955-327
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 15955-327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Orit Laboratories Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Levetiracetam 02)
This document appears to be an excerpt from a clinical trial study, presenting some data related to the patients and their prescription drugs. The given table shows the number of patients who received a placebo treatment and the number of patients who were administered Levetiracetam, which is an anticonvulsant drug. The data is divided based on the drug dosage, which is 1000mg/day and 3000mg/day. However, given the shortness and lack of context of this text, it is not possible to infer any further information.*
Figure 2 (Levetiracetam 03)
This appears to be a chart or graph displaying percentages of patients for a study involving a placebo group and two different dosages of a medication called Levetiracetam. The percentages may represent the number of patients who responded positively to the treatment at each dosage level. However, without more context it is difficult to say for certain.*
Figure 3 (Levetiracetam 04)
The given text provides information about the percentage of patients in two different groups: Placebo and Levetiracetam. However, the specific details of the groups and their conditions have not been given. The percentage of patients is mentioned for the two groups as 14.4% and 39.4%, respectively. Additionally, it is noted that the number of patients in the Placebo group is 104 and that in the Levetiracetam group is 180. It seems that this text may represent data from a research study or clinical trial, but without additional information, further interpretation of the text is not possible.*
Figure 4 (Levetiracetam 05)
This appears to be a table with three columns, displaying percentages. There are two rows and the first row has the heading "% of Patients" while the second row has "%", "Placebo (N=97)", and "Levetiracetam (N=101)" in separate columns. Unfortunately, there isn't enough context to know what the percentages refer to.*
Figure 6 (Levetiracetam 06)
Principal Display Panel (473 mL Bottle Label)
Levetiracetam USP is an oral solution with a concentration of 100mg/mL. The package insert should be consulted for recommended dosage. The medication should be stored in a tightly sealed, light-resistant container at a temperature between 20°C and 25°C. Levetiracetam is manufactured by Silrx Pharmaceuticals, Inc. and distributed by Orit Laboratories LLC. This product should be dispensed with a medication guide and kept away from children. No further information is available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
